[{"orgOrder":0,"company":"Yunovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yunovia Gets MFDS Approval for Phase 1 MAD Study of GLP-1 Agonist","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ID110521156","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"Yunovia","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Yunovia \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"Yunovia \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Yunovia

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FNCE 2024
                          Not Confirmed
                          FNCE 2024
                          Not Confirmed

                          Details : ID110521156 is an orally available small molecule agonist of the GLP-1 receptor. It is being developed for the treatment of obesity and diabetes

                          Brand Name : ID110521156

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 27, 2024

                          Lead Product(s) : ID110521156

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank